A 5-year-old female presented to the emergency department with a 24-hour history of nausea, vomiting and mental status changes. Imaging demonstrated hemorrhage from a suprasellar mass consistent with an optic nerve glioma. The patient was taken to surgery for an open biopsy and hematoma evacuation. Pathology revealed a grade 3 fibrillary astrocytoma. She was subsequently treated with carboplatin and vincristine and is now 2 years out without evidence of recurrence. Apoplexy is a rare presentation for an optic pathway glioma. To the authors’ knowledge, this is the first reported case in the pediatric population. Clinical presentation appears similar to the symptoms observed in pituitary apoplexy. Timely surgery should be directed at obtaining diagnostic tissue, prevention of long-term nervous system damage and evacuation of the hematoma where feasible.

Keywords:
Apoplexy, Astrocytoma, Intracerebral hemorrhage, Optic glioma
1.
Lavin PJ, McCrary JA 3rd, Roessmann U, Ellenberger C Jr: Chiasmal apoplexy: hemorrhage from a cryptic vascular malformation in the optic chiasm. Neurology 1984;34:1007–1011.
2.
Lejeune JP, Hladky JP, Dupard T, Parent M, Hache JC, Christiaens JL: Opticochiasmatic apoplexy (in French). Neurochirurgie 1990;36:303–307.
3.
Muragaki Y, Ujiie H, Ohno M, Kubo O, Hori T: Optic nerve arteriovenous malformation causing optic apoplexy: case report. Neurosurgery 2002;51:1075–1078, discussion 1078.
4.
Sasagawa Y, Akai T, Sasaki T, Iizuka H: Chiasmal and/or optic nerve apoplexy due to rupture of vascular malformation – case report. Neurol Med Chir (Tokyo) 2008;48:460–465.
5.
Mohr G, Hardy J, Gauvin P: Chiasmal apoplexy due to ruptured cavernous hemangioma of the optic chiasm. Surg Neurol 1985;24:636–640.
6.
Regli LP, de Tribolet N: Chiasmatic apoplexy caused by rupture of a cavernoma (in French). Neurochirurgie 1989;35:102–103.
7.
Santos-Ditto RA, Santos-Franco JA, Pinos-Gavilanes MW: Cavernous angioma of the second cranial nerve and chiasmatic apoplexy. Neurocirugia (Astur) 2007;18:47–51.
8.
Maitland CG, Abiko S, Hoyt WF, Wilson CB, Okamura T: Chiasmal apoplexy: report of four cases. J Neurosurg 1982;56:118–122.
9.
Yokoyama S, Takayama K, Sueda M, Ishikawa Y, Hirano H: Optic nerve glioma manifesting as intratumoral hemorrhage in a pregnant woman – case report. Neurol Med Chir (Tokyo) 2003;43:559–562.
10.
Charles NC, Nelson L, Brookner AR, Lieberman N, Breinin GM: Pilocytic astrocytoma of the optic nerve with hemorrhage and extreme cystic degeneration. Am J Ophthalmol 1981;92:691–695.
11.
Applegate LJ, Pribram HF: Hematoma of optic nerve glioma – a cause for sudden proptosis: magnetic resonance imaging findings. J Clin Neuroophthalmol 1989;9:15–19.
12.
Jordan DR, Anderson RL, White GL Jr, Mamalis N: Acute visual loss due to a calcified optic nerve glioma. Can J Ophthalmol 1989;24:335–339.
13.
Pakzaban P, Westmark K, Westmark R: Chiasmal apoplexy due to hemorrhage from a pituitary adenoma into the optic chiasm: case report. Neurosurgery 2000;46:1511–1513, discussion 1513–1514.
14.
McLeod AR: Acute blindness in childhood optic glioma caused by hematoma. J Pediatr Ophthalmol Strabismus 1983;20:31–33.
15.
Mori K, Takeuchi J, Handa H: Subdural effusion and brain tumor: case report and survey of the literature. Surg Neurol 1975;3:257–260.
16.
Hovland KR, Ellis PP: Hemorrhagic glaucoma with optic nerve glioma. Arch Ophthalmol 1966;75:806–809.
17.
Laws ER: Pituitary tumor apoplexy: a review. J Intensive Care Med 2008;23:146–147.
18.
Della Puppa A, Zustovich F, Gardiman M, Manara R, Cecchin D, Scienza R: Haemorrhagic presentation of low-grade glioma in adults. Acta Neurochir (Wien) 2007;149:1151–1155, discussion 1155.
19.
Jaing TH, Lin KL, Tsay PK, Hsueh C, Hung PC, Wu CT, Tseng CK: Treatment of optic pathway hypothalamic gliomas in childhood: experience with 18 consecutive cases. J Pediatr Hematol Oncol 2008;30:222–224.
20.
de Keizer RJ, de Wolff-Rouendaal D, Bots GT, Thomeer RT, Brouwer OF, Vielvoye GJ: Optic glioma with intraocular tumor and seeding in a child with neurofibromatosis. Am J Ophthalmol 1989;108:717–725.
21.
Moharir M, London K, Howman-Giles R, North K: Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 2010;37:1309–1317.
22.
Zoeller GK, Brathwaite CD, Sandberg DI: Malignant transformation of an optic pathway glioma without prior radiation therapy. J Neurosurg Pediatr 2010;5:507–510.
23.
Iraci G, Gerosa M, Scanarini M, Tomazzoli L, Fiore DL, Pardatscher K, Rigobello L, Secchi AG: Anterior optic gliomas with precocious or pseudoprecocious puberty. Childs Brain 1980;7:314–324.
24.
Gupta R, Suri V, Arora R, Sharma MC, Mishra S, Singh M, Sarkar C: Suprasellar ganglioglioma presenting with diabetes insipidus in a young boy: a rare clinical presentation. Childs Nerv Syst 2010;26:255–258.
25.
Tang TT, Whelan HT, Meyer GA, Strother DR, Blank EL, Camitta BM, Franciosi RA: Optic chiasm glioma associated with inappropriate secretion of antidiuretic hormone, cerebral ischemia, nonobstructive hydrocephalus and chronic ascites following ventriculoperitoneal shunting. Childs Nerv Syst 1991;7:458–461.
26.
Drake AJ, Lowis SP, Bouffet E, Crowne EC: Growth hormone hypersecretion in a girl with neurofibromatosis type 1 and an optic nerve glioma: resolution following chemotherapy. Horm Res 2000;53:305–308.
27.
Drimmie FM, MacLennan AC, Nicoll JA, Simpson E, McNeill E, Donaldson MD: Gigantism due to growth hormone excess in a boy with optic glioma. Clin Endocrinol (Oxf) 2000;53:535–538.
28.
Cnossen MH, Stam EN, Cooiman LC, Simonsz HJ, Stroink H, Oranje AP, Halley DJ, de Goede-Bolder A, Niermeijer MF, de Muinck Keizer-Schrama SM: Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 1997;100:667–670.
29.
Ahn Y, Cho BK, Kim SK, Chung YN, Lee CS, Kim IH, Yang SW, Kim HS, Kim HJ, Jung HW, Wang KC: Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst 2006;22:1136–1142.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.